PURPOSE OF REVIEW: This article presents an update on the clinical aspects of human prion disease, including the wide spectrum of their presentations. RECENT FINDINGS: Prion diseases, a group of disorders caused by abnormally shaped proteins called prions, occur in sporadic (Jakob-Creutzfeldt disease), genetic (genetic Jakob-Creutzfeldt disease, Gerstmann-Sträussler-Scheinker syndrome, and fatal familial insomnia), and acquired (kuru, variant Jakob-Creutzfeldt disease, and iatrogenic Jakob-Creutzfeldt disease) forms. This article presents updated information on the clinical features and diagnostic methods for human prion diseases. New antemortem potential diagnostic tests based on amplifying prions in order to detect them are showing very high specificity. Understanding of the diversity of possible presentations of human prion diseases continues to evolve, with some genetic forms progressing slowly over decades, beginning with dysautonomia and neuropathy and progressing to a frontal-executive dementia with pathology of combined prionopathy and tauopathy. Unfortunately, to date, all human prion disease clinical trials have failed to show survival benefit. A very rare polymorphism in the prion protein gene recently has been identified that appears to protect against prion disease; this finding, in addition to providing greater understanding of the prionlike mechanisms of neurodegenerative disorders, might lead to potential treatments. SUMMARY: Sporadic Jakob-Creutzfeldt disease is the most common form of human prion disease. Genetic prion diseases, resulting from mutations in the prion-related protein gene (PRNP), are classified based on the mutation, clinical phenotype, and neuropathologic features and can be difficult to diagnose because of their varied presentations. Perhaps most relevant to this Continuum issue on neuroinfectious diseases, acquired prion diseases are caused by accidental transmission to humans, but fortunately, they are the least common form and are becoming rarer as awareness of transmission risk has led to implementation of measures to prevent such occurrences.
PURPOSE OF REVIEW: This article presents an update on the clinical aspects of humanprion disease, including the wide spectrum of their presentations. RECENT FINDINGS:Prion diseases, a group of disorders caused by abnormally shaped proteins called prions, occur in sporadic (Jakob-Creutzfeldt disease), genetic (genetic Jakob-Creutzfeldt disease, Gerstmann-Sträussler-Scheinker syndrome, and fatal familial insomnia), and acquired (kuru, variant Jakob-Creutzfeldt disease, and iatrogenic Jakob-Creutzfeldt disease) forms. This article presents updated information on the clinical features and diagnostic methods for humanprion diseases. New antemortem potential diagnostic tests based on amplifying prions in order to detect them are showing very high specificity. Understanding of the diversity of possible presentations of humanprion diseases continues to evolve, with some genetic forms progressing slowly over decades, beginning with dysautonomia and neuropathy and progressing to a frontal-executive dementia with pathology of combined prionopathy and tauopathy. Unfortunately, to date, all humanprion disease clinical trials have failed to show survival benefit. A very rare polymorphism in the prion protein gene recently has been identified that appears to protect against prion disease; this finding, in addition to providing greater understanding of the prionlike mechanisms of neurodegenerative disorders, might lead to potential treatments. SUMMARY:Sporadic Jakob-Creutzfeldt disease is the most common form of humanprion disease. Genetic prion diseases, resulting from mutations in the prion-related protein gene (PRNP), are classified based on the mutation, clinical phenotype, and neuropathologic features and can be difficult to diagnose because of their varied presentations. Perhaps most relevant to this Continuum issue on neuroinfectious diseases, acquired prion diseases are caused by accidental transmission to humans, but fortunately, they are the least common form and are becoming rarer as awareness of transmission risk has led to implementation of measures to prevent such occurrences.
Authors: Gábor G Kovács; Maria Puopolo; Anna Ladogana; Maurizio Pocchiari; Herbert Budka; Cornelia van Duijn; Steven J Collins; Alison Boyd; Antonio Giulivi; Mike Coulthart; Nicole Delasnerie-Laupretre; Jean Philippe Brandel; Inga Zerr; Hans A Kretzschmar; Jesus de Pedro-Cuesta; Miguel Calero-Lara; Markus Glatzel; Adriano Aguzzi; Matthew Bishop; Richard Knight; Girma Belay; Robert Will; Eva Mitrova Journal: Hum Genet Date: 2005-11-15 Impact factor: 4.132
Authors: P Sanchez-Juan; A Green; A Ladogana; N Cuadrado-Corrales; R Sáanchez-Valle; E Mitrováa; K Stoeck; T Sklaviadis; J Kulczycki; K Hess; M Bodemer; D Slivarichová; A Saiz; M Calero; L Ingrosso; R Knight; A C J W Janssens; C M van Duijn; I Zerr Journal: Neurology Date: 2006-08-22 Impact factor: 9.910
Authors: Matthias Schmitz; Elisabeth Ebert; Katharina Stoeck; André Karch; Steven Collins; Miguel Calero; Theodor Sklaviadis; Jean-Louis Laplanche; Ewa Golanska; Ines Baldeiras; Katsuya Satoh; Raquel Sanchez-Valle; Anna Ladogana; Anders Skinningsrud; Anna-Lena Hammarin; Eva Mitrova; Franc Llorens; Yong Sun Kim; Alison Green; Inga Zerr Journal: Mol Neurobiol Date: 2015-05-07 Impact factor: 5.590
Authors: Ignazio Cali; Cathleen J Miller; Joseph E Parisi; Michael D Geschwind; Pierluigi Gambetti; Lawrence B Schonberger Journal: Acta Neuropathol Commun Date: 2015-06-25 Impact factor: 7.801
Authors: Atul Maheshwari; Michael Fischer; Pierluigi Gambetti; Alicia Parker; Aarthi Ram; Claudio Soto; Luis Concha-Marambio; Yvonne Cohen; Ermias D Belay; Ryan A Maddox; Simon Mead; Clay Goodman; Joseph S Kass; Lawrence B Schonberger; Haitham M Hussein Journal: Emerg Infect Dis Date: 2015-05 Impact factor: 6.883
Authors: Jonathan P Clewley; Carole M Kelly; Nick Andrews; Kelly Vogliqi; Gary Mallinson; Maria Kaisar; David A Hilton; James W Ironside; Philip Edwards; Linda M McCardle; Diane L Ritchie; Reza Dabaghian; Helen E Ambrose; O Noel Gill Journal: BMJ Date: 2009-05-21
Authors: Mireya Fernández-Fournier; David C Perry; Maria Carmela Tartaglia; Mary de May; Adam Boxer; Giovanni Coppola; Chadwick W Christine; Eric J Huang; William W Seeley; Bruce L Miller; Steven J DeArmond; Lea T Grinberg; Michael D Geschwind Journal: JAMA Neurol Date: 2017-05-01 Impact factor: 18.302
Authors: Adam M Staffaroni; Fanny M Elahi; Dana McDermott; Kacey Marton; Elissaios Karageorgiou; Simone Sacco; Matteo Paoletti; Eduardo Caverzasi; Christopher P Hess; Howard J Rosen; Michael D Geschwind Journal: Semin Neurol Date: 2017-12-05 Impact factor: 3.420
Authors: Joanna E Pankiewicz; Sandrine Sanchez; Kent Kirshenbaum; Regina B Kascsak; Richard J Kascsak; Martin J Sadowski Journal: Mol Neurobiol Date: 2018-07-09 Impact factor: 5.590